Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection
- Biology, PsychologyFrontiers in Pharmacology
Some prematurely optimistic points of view, promoting a large prescription of fluvoxamine in patients with COVID-19, are thought to be reasonably tempered.
Mechanisms of action of fluvoxamine for COVID-19: a historical review
- Psychology, MedicineMolecular Psychiatry
A possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders and schizophrenia in offspring is discussed and fluvoxamine is the most attractive drug for mild to moderate subjects with CO VID-19.
A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies
- Medicine, BiologyBiomedicine & Pharmacotherapy
SHOWING 1-2 OF 2 REFERENCES
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
- Medicine, PsychologyThe Lancet Global Health
Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis
- Biology, MedicineScience Translational Medicine
The contribution of S1R to the restraint of the inflammatory response is revealed and this work identifies sigma-1 receptor (S1R) as an essential inhibitor of cytokine production in a preclinical model of septic shock.